Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy

Sponsor
Mount Sinai Hospital, Canada
Study ID
NCT00813059
Phase
PHASE2
Status
Unknown

Conditions

  • Non-arteritic Anterior Ischemic Optic Neuropathy

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic nerve (the "cable" going from the eye to the brain) resulting in decreased vision. About 15% of patients will experience NAION in the second eye; many of these patients will be left legally blind. Currently, there is no treatment for NAION and for patients in whom the second eye becomes involved by the disease the outcome can be devastating. The investigators are conducting a study where the investigators will inject a medication into the involved eye of patients with NAION. This medication might decrease the swelling of the optic nerve and improve their vision in that eye.

Key Dates

First listed
Dec 22, 2008
Start date
Feb 28, 2009
Status verified
Feb 2012
Primary completion
Jun 30, 2012
Completion
Jun 30, 2012

Study Design

Enrollment
10 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Percentage of patients who gained three or more lines of vision at six months [ Time Frame: 6 months ]

Central Contacts

Related Studies